Jason Richardson was named Chief Financial Officer of Inogen Inc, succeeding Michael Bourque, effective April 6, 2026. As of November 6, 2026, Inogen Inc has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 30, 2026 to November 5, 2026, naming 2 appointments and 1 departure (Form 8-K, March 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Inogen Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-05
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-01
- · In / out: In · Person: Vafa Jamali · 8-K, 2026-04-06
- · In / out: In · Person: Jason Richardson · Role: Chief Financial Officer · Effective: 2026-04-06 · 8-K, 2026-03-30
Inogen Inc reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-30 to 2026-11-05. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Inogen Inc files it.
Also on the record for Inogen Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Inogen Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Inogen Inc and the records around it.
Inogen Inc elsewhere on the record
Companies that share a holder
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Inogen Inc
Get an email when Inogen Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Inogen Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Inogen Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inogen Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-05 | Reported | not named in the filing | 8-K, 2026-11-05 | ||
| 2026-07-01 | Reported | not named in the filing | 8-K, 2026-07-01 | ||
| 2026-04-06 | In | 8-K, 2026-04-06 | |||
| 2026-03-30 | In | Chief Financial Officer | 2026-04-06 | 8-K, 2026-03-30 | |
| 2026-03-30 | Out | Chief Financial Officer | 8-K, 2026-03-30 |
Who leads Inogen Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Jason Richardson, appointed, effective 2026-04-06 (filed 2026-03-30).
New leaders reset buying decisions — get the Full Report on Inogen Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Inogen Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Inogen IncEvery change, in the filing's words
Reported
CEO Transition On October 30, 2026, the Board of Directors ("Board") of the Company appointed Andrew ("Andy") P. Reding, the Company's current Chief Operating Officer, to serve as President and Chief Executive Officer ("CEO") of the Company, effective October 30, 2026 (the "effective date").
- In addition, on October 30, 2026, the Board, upon recommendation of the Nominating and Governance Committee of the Board, appointed Mr. Reding to serve as a Class III director of the Company, effective October 30, 2026, with a term expiring at the annual meeting of stockholders to be held in 2029.
- Mr. Reding succeeds Kevin R.M. Smith in the positions of President and CEO.
- Mr. Smith's role as an officer and employee of the Company ended effective October 30, 2026.
- In connection with his appointment as President and CEO, Mr. Reding will no longer serve as Chief Operating Officer, and the responsibilities of that role will be assumed by Mr. Reding as President and CEO.
- The Company does not intend to appoint a successor Chief Operating Officer at this time.
- Mr. Reding, 56, has served as the Chief Operating Officer since July 2026.
- Previously, he served as Chief Commercial Officer of Viant Medical from September 2020 to March 2026 where he led the commercial function and teams supporting complex medical device design and manufacturing programs.
- Prior to joining Viant Medical, Mr. Reding served as Vice President and General Manager at Hillrom Respiratory Health from 2015 to 2020.
- Prior to that, he held a variety of senior leadership roles at Trumpf Medical Systems, which was acquired by Hillrom.
Reported
On June 2, 2026, the Board of Directors ("Board") of Inogen, Inc. (the "Company") appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer ("COO") of the Company, effective July 6, 2026.
- Mr. Reding, 56, served as Chief Commercial Officer of Viant Medical from September 2020 to March 2026 where he led the commercial function and teams supporting complex medical device design and manufacturing programs.
- Prior to joining Viant Medical, Mr. Reding served as Vice President and General Manager at Hillrom Respiratory Health from 2015 to 2020.
- Prior to that, he held a variety of senior leadership roles at Trumpf Medical Systems, which was acquired by Hillrom.
- Mr. Reding received a masters degree in business and administration from the University of South Carolina and a bachelor's degree in business administration and English from Marquette University.
- On June 2, 2026, the Board, upon the recommendation of the Compensation Committee of the Board (the "Compensation Committee"), approved, and the Company entered into, an employment and severance agreement with Mr. Reding (the "employment agreement"), effective July 6, 2026 (the "Effective Date").
- Mr. Reding's employment under the employment agreement will begin on the Effective Date and is at will and may be terminated at any time by the Company or by Mr. Reding.
- Pursuant to the employment agreement, Mr. Reding will receive an annual base salary of $500,000 and a target annual performance bonus opportunity of seventy percent (70%) of his annual base salary.
Appointed: Vafa Jamali
On April 6, 2026, the Board also appointed Mr. Jamali to the Audit Committee and the Compliance Committee, effective as of the Effective Date.
- On April 6, 2026, the Board appointed Vafa Jamali as a Class I director, effective as of the Effective Date, to serve a term expiring at the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.
- The Board has determined that Mr. Jamali satisfies the independence standards of The Nasdaq Stock Market LLC.
- Mr. Jamali, 56, served as Chairman and Chief Executive Officer of ZimVie Inc., a medical technology company, from February 2021 to November 2025, where he led the company's Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability.
- Previously, Mr. Jamali served as the Chief Commercial Officer of Rockley Photonics, a silicon photonics company, where he led commercial strategic planning for the early-stage company from October 2020 until joining ZimVie.
- Prior to that, Mr. Jamali served as Senior Vice President and President, Respiratory, Gastrointestinal and Informatics ("RGI") of Medtronic plc from May 2017 until October 2020.
Appointed: Jason Richardson, Chief Financial Officer, effective 2026-04-06
On March 24, 2026, the Board of Directors ("Board") of Inogen, Inc. (the "Company") appointed Jason Richardson to serve as Executive Vice President, Chief Financial Officer and Treasurer ("CFO") of the Company, effective April 6, 2026.
Departing: Michael Bourque, Chief Financial Officer
On March 24, 2026, in connection with the appointment of Mr. Richardson as the Company's new Chief Financial Officer, Michael Bourque, Executive Vice President, Finance, Chief Financial Officer, and Treasurer, notified the Company of his intention to step down as an officer of the Company effective upon the date Mr. Richardson commences employment with the Company.
- Most recently, Mr. Richardson, 49, served as Chief Financial Officer and Vice President of the Health System and Technologies Segment of Baxter International Inc. (NYSE: BAX) since 2023.
- He also served as Vice President of Finance Americas and Global Business Units at Baxter from 2021 to 2023.
- Prior to Baxter's acquisition of Hillrom, Mr. Richardson held a variety of senior finance leadership roles at Hillrom, including over its Respiratory Health business.
- Mr. Richardson received a bachelor's degree in accounting and finance from Indiana University.
- On March 24, 2026, the Board, upon the recommendation of the Compensation Committee of the Board, approved, and the Company entered into, an employment and severance agreement with Mr. Richardson (the "employment agreement"), effective April 6, 2026 (the "Effective Date").
- Mr. Richardson's employment under the employment agreement will begin on the Effective Date and is at will and may be terminated at any time by the Company or by Mr. Richardson.
- Pursuant to the employment agreement, Mr. Richardson will receive an annual base salary of $525,000 and a target annual performance bonus opportunity of seventy percent (70%) of his annual base salary.
Tools for this story
Each opens in a new tab, filled in for Inogen Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.